Global Pharma Sustained Release Agent 麻豆原创 Research Report 2023

Publication ID:

PB502233890

Publication Date:

February 22, 2023

Pages:

103

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Pharma Sustained Release Agent market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Pharma Sustained Release Agent is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Pharma Sustained Release Agent is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Pharma Sustained Release Agent include Teva Pharmaceutical Industries, Mylan N.V., Valeant Pharmaceuticals International, Pfizer, Sun Pharmaceutical Industries, Novartis AG, AstraZeneca, GlaxoSmithKline and Allergan, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharma Sustained Release Agent, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharma Sustained Release Agent.
The Pharma Sustained Release Agent market size, estimations, and forecasts are provided in terms of sales volume (Kiloton) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pharma Sustained Release Agent market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharma Sustained Release Agent manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Teva Pharmaceutical Industries
Mylan N.V.
Valeant Pharmaceuticals International
Pfizer
Sun Pharmaceutical Industries
Novartis AG
AstraZeneca
GlaxoSmithKline
Allergan
Janssen Pharmaceuticals
Mayne Pharma Group
BASF
International Flavors & Fragrances
Ashland Global
Evonik Industries
Croda International
Gattefosse
Merck KGaA
Segment by Type
Gelatin
Polymers
Minerals
Sugars
Chitosan
Segment by Application
Pharmaceutical
Health Care
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pharma Sustained Release Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pharma Sustained Release Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Pharma Sustained Release Agent 麻豆原创 Overview
1.1 Product Overview and Scope of Pharma Sustained Release Agent
1.2 Pharma Sustained Release Agent Segment by Type
1.2.1 Global Pharma Sustained Release Agent 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Gelatin
1.2.3 Polymers
1.2.4 Minerals
1.2.5 Sugars
1.2.6 Chitosan
1.3 Pharma Sustained Release Agent Segment by Application
1.3.1 Global Pharma Sustained Release Agent 麻豆原创 Value by Application: (2023-2029)
1.3.2 Pharmaceutical
1.3.3 Health Care
1.3.4 Others
1.4 Global Pharma Sustained Release Agent 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Pharma Sustained Release Agent Revenue 2018-2029
1.4.2 Global Pharma Sustained Release Agent Sales 2018-2029
1.4.3 Global Pharma Sustained Release Agent 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Pharma Sustained Release Agent 麻豆原创 Competition by Manufacturers
2.1 Global Pharma Sustained Release Agent Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Pharma Sustained Release Agent Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Pharma Sustained Release Agent Average Price by Manufacturers (2018-2023)
2.4 Global Pharma Sustained Release Agent Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Pharma Sustained Release Agent, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pharma Sustained Release Agent, Product Type & Application
2.7 Pharma Sustained Release Agent 麻豆原创 Competitive Situation and Trends
2.7.1 Pharma Sustained Release Agent 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pharma Sustained Release Agent Players 麻豆原创 Share by Revenue
2.7.3 Global Pharma Sustained Release Agent 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pharma Sustained Release Agent Retrospective 麻豆原创 Scenario by Region
3.1 Global Pharma Sustained Release Agent 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Pharma Sustained Release Agent Global Pharma Sustained Release Agent Sales by Region: 2018-2029
3.2.1 Global Pharma Sustained Release Agent Sales by Region: 2018-2023
3.2.2 Global Pharma Sustained Release Agent Sales by Region: 2024-2029
3.3 Global Pharma Sustained Release Agent Global Pharma Sustained Release Agent Revenue by Region: 2018-2029
3.3.1 Global Pharma Sustained Release Agent Revenue by Region: 2018-2023
3.3.2 Global Pharma Sustained Release Agent Revenue by Region: 2024-2029
3.4 North America Pharma Sustained Release Agent 麻豆原创 Facts & Figures by Country
3.4.1 North America Pharma Sustained Release Agent 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Pharma Sustained Release Agent Sales by Country (2018-2029)
3.4.3 North America Pharma Sustained Release Agent Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pharma Sustained Release Agent 麻豆原创 Facts & Figures by Country
3.5.1 Europe Pharma Sustained Release Agent 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Pharma Sustained Release Agent Sales by Country (2018-2029)
3.5.3 Europe Pharma Sustained Release Agent Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pharma Sustained Release Agent 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Pharma Sustained Release Agent 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Pharma Sustained Release Agent Sales by Country (2018-2029)
3.6.3 Asia Pacific Pharma Sustained Release Agent Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Pharma Sustained Release Agent 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Pharma Sustained Release Agent 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Pharma Sustained Release Agent Sales by Country (2018-2029)
3.7.3 Latin America Pharma Sustained Release Agent Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Pharma Sustained Release Agent 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Pharma Sustained Release Agent 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Pharma Sustained Release Agent Sales by Country (2018-2029)
3.8.3 Middle East and Africa Pharma Sustained Release Agent Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pharma Sustained Release Agent Sales by Type (2018-2029)
4.1.1 Global Pharma Sustained Release Agent Sales by Type (2018-2023)
4.1.2 Global Pharma Sustained Release Agent Sales by Type (2024-2029)
4.1.3 Global Pharma Sustained Release Agent Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Pharma Sustained Release Agent Revenue by Type (2018-2029)
4.2.1 Global Pharma Sustained Release Agent Revenue by Type (2018-2023)
4.2.2 Global Pharma Sustained Release Agent Revenue by Type (2024-2029)
4.2.3 Global Pharma Sustained Release Agent Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Pharma Sustained Release Agent Price by Type (2018-2029)
5 Segment by Application
5.1 Global Pharma Sustained Release Agent Sales by Application (2018-2029)
5.1.1 Global Pharma Sustained Release Agent Sales by Application (2018-2023)
5.1.2 Global Pharma Sustained Release Agent Sales by Application (2024-2029)
5.1.3 Global Pharma Sustained Release Agent Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Pharma Sustained Release Agent Revenue by Application (2018-2029)
5.2.1 Global Pharma Sustained Release Agent Revenue by Application (2018-2023)
5.2.2 Global Pharma Sustained Release Agent Revenue by Application (2024-2029)
5.2.3 Global Pharma Sustained Release Agent Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Pharma Sustained Release Agent Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Teva Pharmaceutical Industries
6.1.1 Teva Pharmaceutical Industries Corporation Information
6.1.2 Teva Pharmaceutical Industries Description and Business Overview
6.1.3 Teva Pharmaceutical Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Teva Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio
6.1.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.2 Mylan N.V.
6.2.1 Mylan N.V. Corporation Information
6.2.2 Mylan N.V. Description and Business Overview
6.2.3 Mylan N.V. Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Mylan N.V. Pharma Sustained Release Agent Product Portfolio
6.2.5 Mylan N.V. Recent Developments/Updates
6.3 Valeant Pharmaceuticals International
6.3.1 Valeant Pharmaceuticals International Corporation Information
6.3.2 Valeant Pharmaceuticals International Description and Business Overview
6.3.3 Valeant Pharmaceuticals International Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Valeant Pharmaceuticals International Pharma Sustained Release Agent Product Portfolio
6.3.5 Valeant Pharmaceuticals International Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Pharma Sustained Release Agent Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Sun Pharmaceutical Industries
6.5.1 Sun Pharmaceutical Industries Corporation Information
6.5.2 Sun Pharmaceutical Industries Description and Business Overview
6.5.3 Sun Pharmaceutical Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sun Pharmaceutical Industries Pharma Sustained Release Agent Product Portfolio
6.5.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.6 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Novartis AG Pharma Sustained Release Agent Product Portfolio
6.6.5 Novartis AG Recent Developments/Updates
6.7 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.4.4 AstraZeneca Pharma Sustained Release Agent Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 GlaxoSmithKline
6.8.1 GlaxoSmithKline Corporation Information
6.8.2 GlaxoSmithKline Description and Business Overview
6.8.3 GlaxoSmithKline Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.8.4 GlaxoSmithKline Pharma Sustained Release Agent Product Portfolio
6.8.5 GlaxoSmithKline Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Corporation Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Allergan Pharma Sustained Release Agent Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 Janssen Pharmaceuticals
6.10.1 Janssen Pharmaceuticals Corporation Information
6.10.2 Janssen Pharmaceuticals Description and Business Overview
6.10.3 Janssen Pharmaceuticals Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Janssen Pharmaceuticals Pharma Sustained Release Agent Product Portfolio
6.10.5 Janssen Pharmaceuticals Recent Developments/Updates
6.11 Mayne Pharma Group
6.11.1 Mayne Pharma Group Corporation Information
6.11.2 Mayne Pharma Group Pharma Sustained Release Agent Description and Business Overview
6.11.3 Mayne Pharma Group Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mayne Pharma Group Pharma Sustained Release Agent Product Portfolio
6.11.5 Mayne Pharma Group Recent Developments/Updates
6.12 BASF
6.12.1 BASF Corporation Information
6.12.2 BASF Pharma Sustained Release Agent Description and Business Overview
6.12.3 BASF Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.12.4 BASF Pharma Sustained Release Agent Product Portfolio
6.12.5 BASF Recent Developments/Updates
6.13 International Flavors & Fragrances
6.13.1 International Flavors & Fragrances Corporation Information
6.13.2 International Flavors & Fragrances Pharma Sustained Release Agent Description and Business Overview
6.13.3 International Flavors & Fragrances Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.13.4 International Flavors & Fragrances Pharma Sustained Release Agent Product Portfolio
6.13.5 International Flavors & Fragrances Recent Developments/Updates
6.14 Ashland Global
6.14.1 Ashland Global Corporation Information
6.14.2 Ashland Global Pharma Sustained Release Agent Description and Business Overview
6.14.3 Ashland Global Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Ashland Global Pharma Sustained Release Agent Product Portfolio
6.14.5 Ashland Global Recent Developments/Updates
6.15 Evonik Industries
6.15.1 Evonik Industries Corporation Information
6.15.2 Evonik Industries Pharma Sustained Release Agent Description and Business Overview
6.15.3 Evonik Industries Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Evonik Industries Pharma Sustained Release Agent Product Portfolio
6.15.5 Evonik Industries Recent Developments/Updates
6.16 Croda International
6.16.1 Croda International Corporation Information
6.16.2 Croda International Pharma Sustained Release Agent Description and Business Overview
6.16.3 Croda International Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Croda International Pharma Sustained Release Agent Product Portfolio
6.16.5 Croda International Recent Developments/Updates
6.17 Gattefosse
6.17.1 Gattefosse Corporation Information
6.17.2 Gattefosse Pharma Sustained Release Agent Description and Business Overview
6.17.3 Gattefosse Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Gattefosse Pharma Sustained Release Agent Product Portfolio
6.17.5 Gattefosse Recent Developments/Updates
6.18 Merck KGaA
6.18.1 Merck KGaA Corporation Information
6.18.2 Merck KGaA Pharma Sustained Release Agent Description and Business Overview
6.18.3 Merck KGaA Pharma Sustained Release Agent Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Merck KGaA Pharma Sustained Release Agent Product Portfolio
6.18.5 Merck KGaA Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pharma Sustained Release Agent Industry Chain Analysis
7.2 Pharma Sustained Release Agent Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pharma Sustained Release Agent Production Mode & Process
7.4 Pharma Sustained Release Agent Sales and 麻豆原创ing
7.4.1 Pharma Sustained Release Agent Sales Channels
7.4.2 Pharma Sustained Release Agent Distributors
7.5 Pharma Sustained Release Agent Customers
8 Pharma Sustained Release Agent 麻豆原创 Dynamics
8.1 Pharma Sustained Release Agent Industry Trends
8.2 Pharma Sustained Release Agent 麻豆原创 Drivers
8.3 Pharma Sustained Release Agent 麻豆原创 Challenges
8.4 Pharma Sustained Release Agent 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Teva Pharmaceutical Industries
Mylan N.V.
Valeant Pharmaceuticals International
Pfizer
Sun Pharmaceutical Industries
Novartis AG
AstraZeneca
GlaxoSmithKline
Allergan
Janssen Pharmaceuticals
Mayne Pharma Group
BASF
International Flavors & Fragrances
Ashland Global
Evonik Industries
Croda International
Gattefosse
Merck KGaA

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.